At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 150 enrolled
Drug / intervention
ASP4070 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Dose-finding Study of ASP4070 - A Randomized, Double-blind, Placebo-controlled, Dose-finding Study in Patients With Cedar Pollinosis Using an Environmental Exposure Chamber -
In Brief
A Phase 2 clinical trial evaluating ASP4070 and Placebo for Rhinitis, Allergic, Seasonal. Completed, enrolled 150 participants across 1 site.
Detailed Summary
The objective of this study was to evaluate the efficacy, safety, and dose-response of ASP4070 vaccinated in patients with cedar pollinosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRhinitis, Allergic, Seasonal
CountriesJapan
CollaboratorsImmunomic Therapeutics, Inc.
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 2017
Enrollment StartApr 2017
Primary CompletionJan 2018
Study CompletionOct 2018
TodayJul 2026
First PostedApr 5, 2017
Enrollment StartApr 13, 2017
Primary CompletionJan 26, 2018
Study CompletionOct 27, 2018
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 9.2 years ago
Interventions
ASP4070drug
Intradermal vaccination at 2-week intervals
Placebodrug
Intradermal vaccination at 2-week intervals